BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32582591)

  • 1. T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies.
    Katsanis E; Sapp LN; Reid SC; Reddivalla N; Stea B
    Front Pediatr; 2020; 8():282. PubMed ID: 32582591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.
    Katsanis E; Sapp LN; Varner N; Koza S; Stea B; Zeng Y
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2034-2039. PubMed ID: 29908231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre.
    Bilmon IA; Kwan J; Gottlieb D; Kerridge I; McGurgan M; Huang G; George B; Hertzberg M; Bradstock KF
    Intern Med J; 2013 Feb; 43(2):191-6. PubMed ID: 22646924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.
    Klein OR; Buddenbaum J; Tucker N; Chen AR; Gamper CJ; Loeb D; Zambidis E; Llosa NJ; Huo JS; Robey N; Holuba MJ; Kasamon YL; McCurdy SR; Ambinder R; Bolaños-Meade J; Luznik L; Fuchs EJ; Jones RJ; Cooke KR; Symons HJ
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):325-332. PubMed ID: 27888014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies.
    Solh MM; Hinojosa G; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
    Adv Hematol; 2021; 2021():8868142. PubMed ID: 33859695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
    Hsu J; Artz A; Mayer SA; Guarner D; Bishop MR; Reich-Slotky R; Smith SM; Greenberg J; Kline J; Ferrante R; Phillips AA; Gergis U; Liu H; Stock W; Cushing M; Shore TB; van Besien K
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):359-365. PubMed ID: 29128555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.
    Bacigalupo A; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Grasso R; Pozzi S; Colombo N; Tedone E; Varaldo R; Raiola AM
    Bone Marrow Transplant; 2015 Jun; 50 Suppl 2():S37-9. PubMed ID: 26039205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1859-66. PubMed ID: 22863841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
    Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
    Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
    Duléry R; Bastos J; Paviglianiti A; Malard F; Brissot E; Battipaglia G; Médiavilla C; Giannotti F; Banet A; de Wyngaert ZV; Ledraa T; Belhocine R; Sestili S; Adaeva R; Lapusan S; Isnard F; Legrand O; Vekhoff A; Rubio MT; Ruggeri A; Mohty M
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1407-1415. PubMed ID: 30871978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
    Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantation.
    Katsanis E; Stea B; Kovacs K; Truscott L; Husnain M; Khurana S; Roe DJ; Simpson RJ
    Transplant Cell Ther; 2022 Jul; 28(7):390.e1-390.e10. PubMed ID: 35460929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.
    Jacoby E; Chen A; Loeb DM; Gamper CJ; Zambidis E; Llosa NJ; Huo J; Cooke KR; Jones R; Fuchs E; Luznik L; Symons HJ
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):112-8. PubMed ID: 26343947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.
    Kasamon YL; Fuchs EJ; Zahurak M; Rosner GL; Symons HJ; Gladstone DE; Huff CA; Swinnen LJ; Brodsky RA; Matsui WH; Borrello I; Shanbhag S; Cooke KR; Ambinder RF; Luznik L; Bolaños-Meade J; Jones RJ
    Biol Blood Marrow Transplant; 2018 May; 24(5):1022-1028. PubMed ID: 29353109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.
    Gorgeis J; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A; Solh M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1861-1866. PubMed ID: 27375124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.
    Kasamon YL; Ambinder RF; Fuchs EJ; Zahurak M; Rosner GL; Bolaños-Meade J; Levis MJ; Gladstone DE; Huff CA; Swinnen LJ; Matsui WH; Borrello I; Brodsky RA; Jones RJ; Luznik L
    Blood Adv; 2017; 1(4):288-292. PubMed ID: 29242852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.